Barbara Ink

Slough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

Journal: The Journal of rheumatology

Published: July 01, 2026

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Journal: Rheumatology (Oxford, England)

Published: October 28, 2025

Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies.

Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies.

Journal: ACR open rheumatology

Published: October 27, 2025

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies.

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies.

Journal: Rheumatology advances in practice

Published: October 06, 2025

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.

Journal: RMD open

Published: July 25, 2025

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.

Journal: Dermatology and therapy

Published: June 25, 2025

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.

Journal: Annals of the rheumatic diseases

Published: June 19, 2025

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Journal: Rheumatology and therapy

Published: May 05, 2025

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.

Journal: The Journal of rheumatology

Published: January 20, 2025

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Journal: Rheumatology and therapy

Published: December 19, 2024

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.

Journal: RMD open

Published: September 20, 2024

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Journal: Rheumatology and therapy

Published: June 16, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026